NCNA

NuCana plc ADR (NCNA) | Rumor.io

NuCana

NCNA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,968

Bullish sentiment (50-day avg)57%

Price to earnings ratio0.02

Market capitalization5.4M

Earnings per share66

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-29.4M

Social

What share of all stock conversation is about NCNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% -0.01

Aug 28

NuCana plc's European patent EP3683225 for anti-cancer compounds has been granted.
The company's stock price has been affected by naked short selling, with some users expressing frustration and anger towards the practice.
Volume for the stock has been significant, with some users noting almost 1 million in volume.

Generated by AI

Sentiment

Of the messages about NCNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	66.67% +16.67	85.77% +4.83
Bearish	—	—	33.33% -16.67	14.23% -4.83

Bullish· Jul 23

Investors are holding strong on NCNA, with many turning from skeptics to believers.
The stock has seen significant price increases, with NCNA reaching $1.36, a +4.62% gain.
The "HODL" (hold on for dear life) community is actively supporting NCNA, with many participants expecting further gains.

Bearish· Oct 21

$NCNA has failed to deliver approved drugs in its 17-year history, with multiple failed drugs and no presence in the market.
The company's recent news and expectations of a price increase were met with a sharp decline, suggesting that shorts may have driven the drop.
The stock's significant fall from over $7 to around $4 in a short period of time has raised concerns about investor dilution and the company's ability to deliver on its combo therapy.

Generated by AI

Topics

Of the messages about NCNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	53.78%
Technical Analysis	—	—	—	43.41%
Analysts	—	—	—	1.33%
Controversies	—	—	—	1.19%
Earnings	—	—	—	0.3%
Macro	—	—	—	0%

Announcements· Sep 3

NuCana plc ($NCNA) announced that it will present data on NUC-7738's synergy with PD-1 inhibitors at the ESMO Congress 2025.
The presentation will take place in Berlin on October 17-21, 2025, and will build on 2024 findings showing a 55% tumor volume reduction in some melanoma patients resistant to prior PD-1 therapies.
NuCana has raised £19M via an at-the-market program and has £8.4M in cash, with management stating that this funding will support operations into 2025.

Controversies· Jul 11

NuCana plc's (NCNA) patent '190 has been ruled to be infringed by Gilead's Sofosbuvir in a German court decision.
This ruling has led to a significant increase in NCNA's stock price, with a 22.21% rise in the last 13 minutes.
The infringement relates to NuCana's patent on a process for the synthesis of a key intermediate used in the production of Sofosbuvir.

Technical Analysis· Jun 11

The stock appears to be in an upward trend, having recently broken above a descending trendline with increased volume, suggesting potential bullish momentum.
The current price is around $0.1934, with the 9 EMA at $0.1884 providing support, and key resistance levels to watch are around $0.1930.
The stock is setting up for a potential rebound, and a break above $0.22 could lead to a run to $0.30-$0.35.

Generated by AI

Community

Of the messages about NCNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	90.91%	61.4%
Newcomers	0%	0%	9.09%	38.6%

Regulars· Oct 7

The regulars are focused on NuCana's (NCNA) potential to reach $8-$10, citing its massive cash runway and catalysts into the end of the year.
The stock has already shown significant gains, with some regulars experiencing a 115% increase from the bottomed chart and others achieving a 140% swing since posting their analysis.
The sector is heating up, with NuCana (NCNA) trading at a fresh high and regulars expecting further gains, with some even suggesting it can easily run to $10 if held.

Newcomers· Jul 23

Newcomers are excited about the stock's price increase, with one person saying they "bought the dip" and another stating they're "stacking" the stock.
Many newcomers are expressing their intention to hold on to the stock, with phrases like "HODL till moons" and "diamond hands clutching tight" appearing frequently.
The price increase has sparked a "moon mode" atmosphere, with many users expressing their hope that the stock will continue to rise, with phrases like "mooning mood activated" and "moon mode engaged".

Generated by AI

Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026 Advancing Additional Indications and Combination Strategies for NUC-7738 Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial results for the second quarter ended June 30, 2026 and provided an update on its clinical development program with its two lead anti-cancer medicines. “NuCana continue

1mo agoYahoo! Finance Canada

Also Discussed

Investors talking about NCNA also mention

#	Name	Attention
1	Healthcare Triangle Inc.HCTI	0%0
2	Incannex Healthcare Inc.IXHL	0.01%0
3	Wang & Lee Group Inc.WLGS	0%0
4	CGBS - Crown LNG Holdings Limited	——
5	Globavend Holdings LimitedGVH	0%0
6	Chanson International Holding Class A Ordinary SharesCHSN	0%0
7	Erayak Power Solution Group Inc. Class A Ordinary SharesRAYA	0%0
8	ABP - Abpro Corporation	——
9	Oriental Rise Holdings Ltd.ORIS	0%0
10	AtlasClear Holdings, Inc.ATCH	0.01%0

NuCana plc ADR

Healthcare
Biotechnology

NuCana plc ADR is a clinical-stage biopharmaceutical company focused on developing cancer medicines using its proprietary ProTide technology. The company’s current work centers on transforming established chemotherapy agents and nucleoside analogs into new therapies designed for oncology use. Its pipeline includes investigational programs aimed at addressing solid tumors and improving how anti-cancer compounds are delivered inside cancer cells. NuCana plc ADR represents the company’s U.S.-traded depositary shares, providing market access to an oncology-focused biotechnology business based in Edinburgh, United Kingdom. In the financial markets, the asset is followed for its drug development pipeline, clinical progress, and broader positioning within the biotechnology sector.

Website

Location

3 Lochside Way

Edinburgh, EH12 9DT

United Kingdom

Social

What share of all stock conversation is about NCNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% -0.01

Aug 28

NuCana plc's European patent EP3683225 for anti-cancer compounds has been granted.
The company's stock price has been affected by naked short selling, with some users expressing frustration and anger towards the practice.
Volume for the stock has been significant, with some users noting almost 1 million in volume.

Generated by AI

Sentiment

Of the messages about NCNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	66.67% +16.67	85.77% +4.83
Bearish	—	—	33.33% -16.67	14.23% -4.83

Bullish· Jul 23

Investors are holding strong on NCNA, with many turning from skeptics to believers.
The stock has seen significant price increases, with NCNA reaching $1.36, a +4.62% gain.
The "HODL" (hold on for dear life) community is actively supporting NCNA, with many participants expecting further gains.

Bearish· Oct 21

$NCNA has failed to deliver approved drugs in its 17-year history, with multiple failed drugs and no presence in the market.
The company's recent news and expectations of a price increase were met with a sharp decline, suggesting that shorts may have driven the drop.
The stock's significant fall from over $7 to around $4 in a short period of time has raised concerns about investor dilution and the company's ability to deliver on its combo therapy.

Generated by AI

Topics

Of the messages about NCNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	53.78%
Technical Analysis	—	—	—	43.41%
Analysts	—	—	—	1.33%
Controversies	—	—	—	1.19%
Earnings	—	—	—	0.3%
Macro	—	—	—	0%

Announcements· Sep 3

NuCana plc ($NCNA) announced that it will present data on NUC-7738's synergy with PD-1 inhibitors at the ESMO Congress 2025.
The presentation will take place in Berlin on October 17-21, 2025, and will build on 2024 findings showing a 55% tumor volume reduction in some melanoma patients resistant to prior PD-1 therapies.
NuCana has raised £19M via an at-the-market program and has £8.4M in cash, with management stating that this funding will support operations into 2025.

Controversies· Jul 11

NuCana plc's (NCNA) patent '190 has been ruled to be infringed by Gilead's Sofosbuvir in a German court decision.
This ruling has led to a significant increase in NCNA's stock price, with a 22.21% rise in the last 13 minutes.
The infringement relates to NuCana's patent on a process for the synthesis of a key intermediate used in the production of Sofosbuvir.

Technical Analysis· Jun 11

The stock appears to be in an upward trend, having recently broken above a descending trendline with increased volume, suggesting potential bullish momentum.
The current price is around $0.1934, with the 9 EMA at $0.1884 providing support, and key resistance levels to watch are around $0.1930.
The stock is setting up for a potential rebound, and a break above $0.22 could lead to a run to $0.30-$0.35.

Generated by AI

Community

Of the messages about NCNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	90.91%	61.4%
Newcomers	0%	0%	9.09%	38.6%

Regulars· Oct 7

The regulars are focused on NuCana's (NCNA) potential to reach $8-$10, citing its massive cash runway and catalysts into the end of the year.
The stock has already shown significant gains, with some regulars experiencing a 115% increase from the bottomed chart and others achieving a 140% swing since posting their analysis.
The sector is heating up, with NuCana (NCNA) trading at a fresh high and regulars expecting further gains, with some even suggesting it can easily run to $10 if held.

Newcomers· Jul 23

Newcomers are excited about the stock's price increase, with one person saying they "bought the dip" and another stating they're "stacking" the stock.
Many newcomers are expressing their intention to hold on to the stock, with phrases like "HODL till moons" and "diamond hands clutching tight" appearing frequently.
The price increase has sparked a "moon mode" atmosphere, with many users expressing their hope that the stock will continue to rise, with phrases like "mooning mood activated" and "moon mode engaged".

Generated by AI

NuCana

Social

Aug 28

Sentiment

Bullish· Jul 23

Bearish· Oct 21

Topics

Announcements· Sep 3

Controversies· Jul 11

Technical Analysis· Jun 11

Community

Regulars· Oct 7

Newcomers· Jul 23

News

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

NuCana plc ADR

Company Information

Location

News

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Social

Aug 28

Sentiment

Bullish· Jul 23

Bearish· Oct 21

Topics

Announcements· Sep 3

Controversies· Jul 11

Technical Analysis· Jun 11

Community

Regulars· Oct 7

Newcomers· Jul 23